Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 12/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrose SCHEMBL5679244 | 1.00 | SLC5A2 (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 | |
| B-D-Galactose SCHEMBL8515088 | 1.00 | SLC5A2 (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 | |
| D-Galactose SCHEMBL2370315 | 1.00 | SLC5A2 (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 | |
| B-D-Galactose SCHEMBL1712843 | 1.00 | SLC5A2 (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 | |
| B-D-Galactose SCHEMBL307802 | 1.00 | SLC5A2 (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 | |
| Beta-D-Glucose SCHEMBL3018938 | 0.87 | APP (0.68) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| D-Galactose SCHEMBL15391861 | 0.87 | APP (0.68) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| B-D-Galactose SCHEMBL307801 | 0.87 | APP (0.68) | APPCYP1A2KDM4EMEN1ALDH1A1 | |
| N-Acetylglucosamine SCHEMBL5692330 | 0.86 | HK1 (0.43) | SLC5A2APPCYP1A2POLB | |
| SCHEMBL3827094 | 0.85 | APP (0.49) | SLC5A2APPCYP1A2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197018-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | US | claimed |
| US-20240158776-A1 | NANOCAGED ENZYMES WITH ENHANCED CATALYTIC ACTIVITY AND INCREASED STABILITY | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| US-11903985-B2 | Gene therapies for lysosomal disorders | PREVAIL THERAPEUTICS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240044869-A1 | ASSAY FOR MEASURING POTENCY OF GENE THERAPY DRUG PRODUCT | PREVAIL THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20230310654-A1 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | PREVAIL THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11718854-B2 | Gene targets for improved enzyme production in fungi | BATTELLE MEMORIAL INSTITUTE (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4192516-A2 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | Prevail Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220325265-A1 | GLUCOCEREBROSIDASE MUTANTS | HOFFMANN-LA ROCHE INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396522-B2 | Bis-acetal-based substrates for imaging exo-glycosidase activity | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-26 | — | — | US | disclosed |
| US-20220177887-A1 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| EP-1861506-A2 | CELLULASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1844330-A2 | METHOD FOR DETERMINING THE BIOGEOCHEMICAL REACTIVITY OF AN ORGANIC AQUEOUS SAMPLE | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007094852-A2 | CELLULOLYTIC ENZYMES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| US-7227158-B1 | Stick-on self-indicating instant radiation dosimeter | JP LABS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7172877-B2 | Methods and compositions for peptide and protein labeling | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006101584-A2 | CELLULASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006079733-A2 | METHOD FOR DETERMINING THE BIOGEOCHEMICAL REACTIVITY OF AN ORGANIC AQUEOUS SAMPLE | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR) | 2006-08-03 | — | — | WO | disclosed |
| US-20060145091-A1 | Self indicating radiation alert dosimeter | JP LABORATORIES INC. | 2006-07-06 | — | — | US | disclosed |
| US-20050233389-A1 | Methods and compositions for peptide and protein labeling | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-10-20 | — | — | US | disclosed |
| US-20040209317-A1 | Methods and compositions for peptide and protein labeling | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233389-A1 | Methods and compositions for peptide and protein labeling | HLCS, BTD, QPCTL | SLC5A2 4585/4885APP 99/4885CYP1A2 4803/4885 |
| US-11396522-B2 | Bis-acetal-based substrates for imaging exo-glycosidase activity | ENGASE, MAN2B2, GALE | SLC5A2 1119/4885APP 2595/4885CYP1A2 3948/4885 |
| US-20220325265-A1 | GLUCOCEREBROSIDASE MUTANTS | GBA1, GBA3, GALC | SLC5A2 347/4885APP 1336/4885CYP1A2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.